FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1878794137> ?p ?o ?g. }

• W1878794137 endingPage "80" @default.
• W1878794137 startingPage "79" @default.
• W1878794137 abstract "Editorial8 May 2009Open Access Challenges in translational research Giulio Cossu Giulio Cossu [email protected] Senior Editor of EMBO Molecular Medicine and Director of the Division of Regenerative Medicine. San Raffaele Scientific Institute and Professor of Histology, University of Milan, Milan, Italy Search for more papers by this author Giulio Cossu Giulio Cossu [email protected] Senior Editor of EMBO Molecular Medicine and Director of the Division of Regenerative Medicine. San Raffaele Scientific Institute and Professor of Histology, University of Milan, Milan, Italy Search for more papers by this author Author Information Giulio Cossu1 1Senior Editor of EMBO Molecular Medicine and Director of the Division of Regenerative Medicine. San Raffaele Scientific Institute and Professor of Histology, University of Milan, Milan, Italy EMBO Mol Med (2009)1:79-80https://doi.org/10.1002/emmm.200900017 PDFDownload PDF of article text and main figures. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions Figures & Info We have seen, with some paternal pride, the first issue of EMBO Molecular Medicine (EMM). I am pleased to see the quality of the articles and the many lively sections of the journal; even more so because despite the excitement for this new initiative, I was slightly apprehensive about what seems to be a never-ending proliferation of scientific journals. In the case of EMM, however, I feel that there is a need to fill the gap that appears to exist between basic research, its application and clinical experimentation, a gap that also impacts on the scientific life and research activity of many of us. To fill this gap we are moving into a largely unexplored territory, where the excitement of providing new therapies for otherwise incurable diseases must often cope with a number of problems and risks. »we are moving into a largely unexplored territory.« The field of stem cell research is currently facing such a challenge. The International Society for Stem Cell Research recently published the Guidelines for Clinical Translation of Stem Cell Research (http://www.isscr.org) in order to advise scientists, clinicians and patients on the necessary steps to be undertaken to start clinical experiments on stem cells with minimal risks and maximal chance of success (Hyun et al, 2008). As a member of the Task force that wrote these guidelines, I experienced the difficulty in writing this document, where almost each word had to be weighed very carefully. On one hand, it was mandatory to propose rigorous controls to make new procedures as safe as possible; on the other hand, it was important to realize that pushing the controls and the rules too far would lead to an arrest of medical progress. Six years ago, an unpredictable, severe adverse event in a trial of gene therapy for children affected by a congenital immune deficiency led to severe restrictions on the clinical use of genetically corrected hematopoietic stem cells, and to heated debates on the safety of retroviral gene transfer vectors (Gaspar & Thrasher, 2005; Williams & Baum, 2003). Since then, five out of twenty children treated in two different clinical trials developed T-cell leukemia that in one case was fatal (Hacein-Bey-Abina et al, 2008; Howe et al, 2008). Is it possible that more pre-clinical work would have prevented this? Probably not, because the problem had never appeared in any of the animals treated with the same procedure during pre-clinical investigation. Could a deeper analysis of the effects of retroviral integration in the human genome have provided useful information? Possibly, but it should be considered that the sophisticated technology currently used to look at viral insertions into the human genome did not exist at the time, and that the wealth of information now available on the subject would not exist had those adverse events never occurred. Most importantly, it should be kept in mind that the large majority of the patients treated with gene therapy for two forms of lethal congenital immunodeficiency are now alive and healthy – thanks to this ‘risky’ therapy (Aiuti et al, 2009; Hacein-Bey-Abina et al, 2008; Howe et al, 2008). While the above problem occurred in a trial conducted by internationally recognized groups with an outstanding record in gene therapy, and fully complying with rigorous safety controls, things may become more fuzzy and complicated when we move to the use of pluripotent or multipotent stem cells. Stem cells are not distinguishable from progenitors by any physical feature, and still only poorly in terms of the antigens they express, therefore the only reliable criterion of identification is their biological activity, that in vivo can only be assessed retrospectively. Anyone can work with stem cells and claim to obtain a biological and/or therapeutic effect, with little chance of being controlled in advance. The explosive proliferation of private clinics all over the world that promise therapies for incurable diseases and are the target of ‘stem cell tourism’ is in part due to the above considerations. Warning against these treatments by academics will have little impact on those who are desperate and see a disease progress daily, taking more and more of their own life or that of their loved ones. Amariglio et al (2009) recently reported that donor cell-derived tumours grew in the CNS of a young teleangectasic patient, transplanted with human fetal neural stem cells in a centre in Russia. The consequences of this situation for the patient and for those who may be treated in the future are not clear and have obviously made the research community apprehensive. The limited information available on the nature of the transplanted cells (Poltavtseva et al, 2003) makes it difficult to predict whether this event is a consequence of inadequate cell characterization or whether it may re-occur in the future, even in the most rigorous and controlled trials. As an obvious and general rule, the cell population to be transplanted should be characterized in deep detail. If fetal or embryonic in nature, strategies should be implemented to either prevent uncontrolled proliferation of transplanted cells, or kill them if such proliferation happens. Also possible contamination by infectious agents should be rigorously assessed. Other issues such as survival, proper differentiation and functional integration in the transplanted tissue are crucial for the success of the transplant but are less relevant to safety. At present, much of this information is not available for the cells transplanted in the patient, and thus it is very difficult to draw conclusions. Nevertheless, several people will soon state that stem cell therapies are dangerous and should be halted until further evidence is accumulated. But how, if trials in patients are stopped? These voices may not remember that many of the first patients receiving bone marrow transplantation (BMT) did not survive (Thomas, 1999); they may not consider that with current regulations, none of the hundreds of thousands of patients who received BMT would be alive today. So precaution must be rigorous and trials controlled as much as possible, but new therapies must continue to be tested. Although it is the stem cell research community that is now confronted by this thorny dilemma, similar challenges are likely to arise wherever advances in basic research open up new possibilities for treatment of diseases. In such cases, the risks involved need to be responsibly balanced with the safety of and the benefits to the patient. To report on these challenges and actively discuss them is essential to successfully overcome them, and I hope that EMM will be your journal of choice to report the results of this novel translational research and that it will become the forum for the scientific community to comment and discuss on the topic. Giulio Cossu References Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I et al (2009) Gene therapy for immunodeficiencies due to adenosine deaminase deficiency. New Engl J Med 360: 447- 458 CrossrefCASPubMedWeb of Science®Google Scholar Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, Paz N, Koren-Michowitz M, Waldman D, Leider-Trejo L et al (2009) Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med Feb 17; 6: e1000029. [Epub ahead of print] CrossrefCASPubMedWeb of Science®Google Scholar Gaspar HB, Thrasher AJ (2005) Gene therapy for severe combined immunodeficiencies. Expert Opin Biol Ther 5: 1175- 1182 CrossrefCASPubMedWeb of Science®Google Scholar Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, Clappier E, Caccavelli L, Delabesse E, Beldjord K et al (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132- 3142 CrossrefCASPubMedWeb of Science®Google Scholar Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, Brugman MH, Pike-Overzet K, Chatters SJ, de Ridder J et al (2008) Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143- 3150 CrossrefCASPubMedWeb of Science®Google Scholar Hyun I, Lindvall O, Ahrlund-Richter L, Cattaneo E, Cavazzana-Calvo M, Cossu G, De Luca M, Fox IJ, Gerstle C, Goldstein RA et al (2008) New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell 3: 607- 609 CrossrefCASPubMedWeb of Science®Google Scholar Poltavtseva RA, Marey MV, Aleksandrova MA, Revishchin AV, Korochkin LI, Sukhikh GT (2002) Evaluation of progenitor cell cultures from human embryos for neurotransplantation. Brain Res Dev Brain Res 134: 149- 154 CrossrefCASPubMedWeb of Science®Google Scholar Thomas ED (1999) Bone marrow transplantation: a review. Semin Hematol 36: 95- 103 CASPubMedWeb of Science®Google Scholar Williams DA, Baum C (2003) Medicine: gene therapy—new challenges ahead. Science 302: 400- 401 CrossrefCASPubMedWeb of Science®Google Scholar Previous ArticleNext Article Volume 1Issue 21 May 2009In this issue ReferencesRelatedDetailsLoading ..." @default.
• W1878794137 created "2016-06-24" @default.
• W1878794137 creator A5019123412 @default.
• W1878794137 date "2009-05-01" @default.
• W1878794137 modified "2023-10-09" @default.
• W1878794137 title "Challenges in translational research" @default.
• W1878794137 cites W1972402361 @default.
• W1878794137 cites W2057879405 @default.
• W1878794137 cites W2063590777 @default.
• W1878794137 cites W2107046588 @default.
• W1878794137 cites W2121444412 @default.
• W1878794137 cites W2149033728 @default.
• W1878794137 cites W2163586576 @default.
• W1878794137 cites W2168466920 @default.
• W1878794137 doi "https://doi.org/10.1002/emmm.200900017" @default.
• W1878794137 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3378115" @default.
• W1878794137 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20049705" @default.
• W1878794137 hasPublicationYear "2009" @default.
• W1878794137 type Work @default.
• W1878794137 sameAs 1878794137 @default.
• W1878794137 citedByCount "2" @default.
• W1878794137 countsByYear W18787941372019 @default.
• W1878794137 crossrefType "journal-article" @default.
• W1878794137 hasAuthorship W1878794137A5019123412 @default.
• W1878794137 hasBestOaLocation W18787941371 @default.
• W1878794137 hasConcept C100631289 @default.
• W1878794137 hasConcept C128544194 @default.
• W1878794137 hasConcept C142724271 @default.
• W1878794137 hasConcept C181199279 @default.
• W1878794137 hasConcept C55493867 @default.
• W1878794137 hasConcept C70721500 @default.
• W1878794137 hasConcept C71924100 @default.
• W1878794137 hasConcept C86803240 @default.
• W1878794137 hasConceptScore W1878794137C100631289 @default.
• W1878794137 hasConceptScore W1878794137C128544194 @default.
• W1878794137 hasConceptScore W1878794137C142724271 @default.
• W1878794137 hasConceptScore W1878794137C181199279 @default.
• W1878794137 hasConceptScore W1878794137C55493867 @default.
• W1878794137 hasConceptScore W1878794137C70721500 @default.
• W1878794137 hasConceptScore W1878794137C71924100 @default.
• W1878794137 hasConceptScore W1878794137C86803240 @default.
• W1878794137 hasIssue "2" @default.
• W1878794137 hasLocation W18787941371 @default.
• W1878794137 hasLocation W18787941372 @default.
• W1878794137 hasLocation W18787941373 @default.
• W1878794137 hasLocation W18787941374 @default.
• W1878794137 hasOpenAccess W1878794137 @default.
• W1878794137 hasPrimaryLocation W18787941371 @default.
• W1878794137 hasRelatedWork W2095926488 @default.
• W1878794137 hasRelatedWork W2135656292 @default.
• W1878794137 hasRelatedWork W2500220643 @default.
• W1878794137 hasRelatedWork W2522105753 @default.
• W1878794137 hasRelatedWork W2834541610 @default.
• W1878794137 hasRelatedWork W3118049886 @default.
• W1878794137 hasRelatedWork W4205886009 @default.
• W1878794137 hasRelatedWork W4281923159 @default.
• W1878794137 hasRelatedWork W4285142023 @default.
• W1878794137 hasRelatedWork W3146937370 @default.
• W1878794137 hasVolume "1" @default.
• W1878794137 isParatext "false" @default.
• W1878794137 isRetracted "false" @default.
• W1878794137 magId "1878794137" @default.
• W1878794137 workType "article" @default.